Latest Research And Development News

Phoslock Environmental Technologies reported a sales recovery in 2025 with further growth expected, backed by resumed production in China and promising European projects, while ongoing litigation clouds the outlook.

Ainsworth Game Technology posted a 10% revenue increase in FY25 to $291 million, driven by strong Asia Pacific growth, while North American challenges weigh on H1 2026 outlook.

CleanSpace Holdings expects modest revenue growth for FY26, hindered by product certification delays and global market challenges, while maintaining a strong cash position and preparing a new respirator launch.

Fisher & Paykel Healthcare posted a 14% revenue increase to NZ$2.31 billion and a 24% rise in net profit to NZ$468.5 million for FY2026, driven by strong hospital product sales and ongoing innovation.

HIQ Limited has locked in non-dilutive funding from the Victorian Government to underpin a $4.9 million project expanding its manufacturing and research footprint in Victoria, supporting its global growth ambitions.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

Strategic Elements Limited is raising up to $1 million via a Share Purchase Plan (SPP) at 3.5 cents per share, with attaching options exercisable at 4 cents, to fuel development in Energy Ink™ and Stealth Technologies.

Island Pharmaceuticals has appointed Mark Herzog as Senior Global Health Security Advisor and secured roles in key Medical Countermeasures Coalition groups, boosting its US biodefence engagement ahead of pivotal Galidesivir Animal Rule studies.

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.

Delorean Corporation has banked a $5.76 million cash refund from the Australian Government’s FY2025 R&D Tax Incentive, underpinning its bioenergy infrastructure growth. Another refund linked to FY2026 expenditure is anticipated next year.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

Unith Ltd (ASX:UNT) posted Q3 FY2026 revenue of A$1.26 million, secured a $2 million finance facility to fuel commercial expansion, and showcased significant advancements in its AI Digital Humans platform, including proprietary streaming technology and SDK launches.